The endothelial cell protein C receptor (EPCR) shares ϳ20% sequence identity with the major histocompatibility complex class 1/CD1 family of molecules, accelerates the thrombin-thrombomodulin-dependent generation of activated protein C, a natural anticoagulant, binds to activated neutrophils, and can undergo translocation from the plasma membrane to the nucleus. Blocking protein C/activated protein C binding to the receptor inhibits not only protein C activation but the ability of the host to respond appropriately to bacterial challenge, exacerbating both the coagulant and inflammatory responses. To understand how EPCR accomplishes these multiple tasks, we solved the crystal structure of EPCR alone and in complex with the phospholipid binding domain of protein C. The structures were strikingly similar to CD1d. A tightly bound phospholipid resides in the groove typically involved in antigen presentation. The protein C binding site is outside this conserved groove and is distal from the membrane-spanning domain. Extraction of the lipid resulted in loss of protein C binding, which could be restored by lipid reconstitution. CD1d augments the immune response by presenting glycolipid antigens. The EPCR structure is a model for how CD1d binds lipids and further suggests additional potential functions for EPCR in immune regulation, possibly including the anti-phospholipid syndrome.
For blood to clot, a series of sequential proteolytic complexes form, each leading to the generation of a new serine protease (1) . The complexes contain the zymogen, a membrane-bound enzyme, a cofactor protein, and Ca 2ϩ ions all assembled on a negatively charged phospholipid surface. Complete complex assembly is essential to rapid activation of the bound zymogen. In most cases, binding of the zymogen and the protease to the membrane is mediated by a specialized vitamin K-dependent domain containing ␥-carboxyglutamic acid (Gla, and referred to as the Gla domain). For these complexes to function efficiently, it is critical that negatively charged phospholipids be mobilized to the cell surface, an event that requires a potent cell agonist (2) .
Balancing the clotting system are several natural anticoagulant mechanisms. One of the most potent is the protein C anticoagulant pathway. The critical nature of the pathway is demonstrated by the clinical observation that homozygous deficiency results in neonatal or embryonic lethality in man and mice (for review, see Ref. 3) . Protein C activation occurs on the surface of the endothelium when thrombin binds to thrombomodulin (for review, see Ref. 4) . Activated protein C (APC) 1 generated by this complex then binds to protein S on negatively charged membrane surfaces and inactivates the critical cofactors, factors Va and VIIIa, preventing further thrombin generation.
Recently protein C activation has been shown to be augmented by EPCR. Direct binding of protein C to EPCR circumvents the requirement for endothelial cell activation for these cells to support protein C activation effectively (5) . Binding of protein C to EPCR has been shown to be mediated almost entirely by the vitamin K-dependent Gla domain (6) , normally considered to be primarily involved in binding to negatively charged phospholipid surfaces.
In addition to binding protein C, EPCR appears to perform other functions. It binds proteinase 3, the autoantigen in Wegener's granulomatosis. This complex then binds to Mac-1 on activated neutrophils (7) where it apparently inhibits tight leukocyte adhesion to activated endothelium. The proteinase 3 and protein C binding sites appear to be distinct. Another property of EPCR is that it can translocate from the membrane surface to the nucleus.
EPCR shares sequence homology with the major histocompatibility complex class 1 (MHC class 1) and CD1 family of molecules (8) . In general, these molecules bind ligands in a deep hydrophobic groove formed by two ␣-helices that overlie the eight-stranded ␤-pleated sheet (9) . CD1 molecules can bind lipid antigens and present these antigens to T cells. Like the CD1 molecules, the structure presented here indicates that EPCR has its groove filled with a lipid molecule, but unlike the CD1 molecules, EPCR is missing the ␣3 domain and does not associate with ␤ 2 -microglobulin. Mutagenesis studies of EPCR have indicated that protein C binding is mediated at the tip of EPCR and does not involve the groove (10 sentially as described previously (11) except that the Chinese hamster ovary cell line Lec 3.2.8.1 was used for expression to shorten the N-linked carbohydrates. rsEPCR was concentrated to 15 mg/ml in TBS (20 mM Tris-HCl, pH 7.5, 100 mM NaCl), 0.02% NaN 3 . 4 M sodium formate was used as a precipitant. Crystals were grown in hanging drops by the vapor diffusion method. Data collection for the native form was performed with a synchrotron x-ray source (National Synchrotron Light Source, X9B) where the crystal diffracted to 2.0 Å and for derivatives was performed on a MAR345 image plate detector (MAR Research, Norderstedt, Hamburg, Germany) mounted on a Rigaku rotating anode x-ray generator (MSC, The Woodlands, TX) and equipped with an Oxford cooling system. The crystals of human rsEPCR belong to the P3 1 21 space group with the cell parameters a ϭ b ϭ 69.6 Å, c ϭ 96.0 Å. The asymmetric unit contains one rsEPCR molecule. The data were processed using the HKL2000 package (12) . The rsEPCR crystal in 6 M sodium formate, TBS, and 0.02% NaN 3 was soaked overnight at room temperature with 10 Ϫ4 M K 2 Pt(SCN) 6 . Three binding sites were revealed. When the rsEPCR crystal in 4 M sodium formate, TBS, and 0.02% NaN 3 was soaked overnight in 10 Ϫ4 M p-chloromercuribenzoate, three derivatized sites were also detected. After solvent flattening and density modification, the phases were used to calculate the electron density map. The electron density was clearly interpretable and allowed placement of 150 consecutive residues. All the calculations were done using CNS (13) . Model building was performed using O software (14) . Data statistics and procedure results are summarized in Table I .
rsEPCR-Protein C Crystallization and Structure DeterminationProtein C was isolated from a vitamin K-dependent protein concentrate (a generous gift from Baxter AG) essentially as described previously (15) . rsEPCR was mixed with protein C at a ratio of 1.1 to 1. The mixture in TBS, 10 mM CaCl 2 , and 0.02% NaN 3 was concentrated to 20 mg/ml. The crystallization condition was: 100 mM KCl, 10 mM MgCl 2 , 10 mM CaCl 2 , 50 mM HEPES, pH 7.0, and 5% (v/v) polyethylene glycol. The crystal was washed for 5-10 s in 100 mM KCl, 10 mM MgCl 2 , 10 mM CaCl 2 , 50 mM HEPES, pH 7.0, and 22% (v/v) polyethylene glycol 400 and then flash cooled on the goniometer head. The resolution limit of the diffraction was about 1.55 Å on the in-house machine. Data were processed using HKL2000. Data statistics are summarized in Table I . The crystal belongs to the P2 1 space group with cell parameters a ϭ 59.22 Å, b ϭ 62.36 Å, c ϭ 71.03 Å, ␤ ϭ 101.81°. The asymmetric unit contains two complexes.
EPCR-APC Binding Assay-Briefly, rsEPCR was used as a competitor to block the binding of active site fluorescently labeled APC to human umbilical vein endothelial cells (HUVECs) (11, 16) . Inhibition of APC binding was analyzed by flow cytometry (16) .
Extraction of Phospholipid from rsEPCR-All extraction experiments were performed at room temperature. 1 ml of 2 mg/ml rsEPCR in TBS, 5 mM EDTA was mixed with 100 l of 10% Triton X-100. After 1 h, 2 ml of 1-butanol/diisopropyl ether (DIPE) (40:60, v/v) was added, and the sample was rocked overnight at room temperature. The mixture was then centrifuged at 2,000 rpm for 2 min (17). The aqueous phase was removed and washed with pure DIPE to remove possible traces of 1-butanol. The organic phase was evaporated under nitrogen to minimize the possible oxidation of the lipid. The dried organic phase served as the source of lipid for functional reconstitution.
Reconstitution of rsEPCR-APC Binding Activity-The delipidated rsEPCR in the aqueous phase was divided into two 300-l aliquots. An equal volume of TBS containing 2% n-octyl-␤-D-glucopyranoside was added to each aliquot of rsEPCR. No additions were made to the first aliquot of delipidated rsEPCR. To the second aliquot we added 4 l of dried lipid extracted from EPCR, and the solution was mixed. The "dried" lipid was a very viscous material that could be pipetted. Tubes were rocked for 2 h at room temperature and then dialyzed overnight against TBS.
RESULTS AND DISCUSSION
To help elucidate how EPCR carries out its wide range of functions, we solved the structure of rsEPCR alone and also bound to the Gla domain of protein C. Although the crystal packing environments for the two crystals were very different, there appeared to be little change in the EPCR structure upon binding the protein C Gla domain. Specifically the root mean square disposition between two non-crystallographically related rsEPCR molecules in the presence of the protein C Gla domain was as large as the difference seen between either rsEPCR in that structure or the rsEPCR crystal formed in the absence of the protein C Gla domain (root mean square disposition, 0.4 Å). The only large shift involved the side chain of the Arg 156 , which moved to open a hydrophobic pocket in EPCR that can accommodate Phe 4 of the protein C Gla domain. The overall fold of rsEPCR is similar to the rest of the members of the MHC class 1 and CD1 families (Fig. 1) . A groove is formed by two ␣-helices overlying a ␤-pleated sheet. In MHC class 1 molecules that bind peptides, the distance between the ␣-helices is larger than in rsEPCR or CD1d. Although the CD1d x-ray structure has been solved (18), the lipid molecule was not modeled. The rsEPCR and the CD1d molecules were superimposed to compare the lipid binding grooves. The comparison revealed that of 18 residues making contacts between rsEPCR and the lipid molecule, seven are identical, and six residues have similar properties in CD1d (Fig. 2) . The other five residues are different, but they belong to part of the structure that does not superimpose.
The protein C Gla domain-rsEPCR crystal provided higher resolution data (1.55 Å) than the crystal of rsEPCR (2.0 Å) alone. This higher resolution data allowed us to identify the bound lipid as either phosphatidylethanolamine or phosphatidylcholine (Fig. 1) . The fatty acid side chains of the lipid interact with the hydrophobic residues within the groove. The helices cover these fatty acid side chains, apparently restricting solvent access (Fig. 3) and perhaps protecting the fatty acids from oxidation. The head group is solvent-exposed compromising exact crystallographic determination.
Although crystallization was attempted between rsEPCR and intact protein C, electron density from only the first 33 amino acid residues of protein C could be identified. Positions 42 and 44 in protein C are known to be highly susceptible to cleavage by chymotrypsin-like enzymes. Cleavage at these sites apparently occurred during crystallization. This fortuitous cleavage may have allowed the crystals to form. Binding of protein C to EPCR is Ca 2ϩ -dependent. The Ca 2ϩ ions in the protein C Gla domain (shown in magenta in Fig. 1 ) are clearly visible in the structure. Only one contact is made between the Ca 2ϩ ions bound to the protein C Gla domain and EPCR (residue Glu 86 of EPCR) (Fig. 4) 4 and Leu 8 of the loop in the protein C appear to be required for protein C binding to phospholipid, which is also a FIG. 1 . The rsEPCR molecule with a portion of the protein C Gla domain and a lipid molecule. In EPCR (yellow ribbon), two ␣-helices and an eight-stranded ␤-sheet create a groove that is filled with phospholipid (the space-filling balls in the center). Binding of Ca 2ϩ ions (magenta spheres) to the protein C Gla domain (green ribbon) exposes the N-terminal loop, which in the absence of EPCR interacts with the phospholipid surfaces on the membrane. There do not appear to be direct interactions between the protein C Gla domain and the lipid molecule located in the groove of rsEPCR. The model of the complex consists of residues 7-177 of rsEPCR and the first 33 residues of the protein C Gla domain (25, 26) .
FIG. 2.
Stereodiagram showing the EPCR molecule in coil presentation. The lipid molecule, and the residues within 3.5Å of the lipid, are represented in the ball-and-stick presentation. Superimposition of EPCR and CD1d1 molecules revealed seven identical (shown in black outline) and six similar amino acids (shown in red outline) within the hydrophobic groove that occupy similar positions. Most of the identical residues are clustered around the less curved fatty acid chain, whereas most of the similar ones are around the kinked chain. Such clustering might be an indication of the different specificity of EPCR and CD1d1 toward fatty acid chains. Prepared using Molscript (26) .   FIG. 3 . Surface representation of the rsEPCR molecule. Electrostatic potentials are mapped on the surface. The head group of the lipid is solvent-exposed (yellow stick model in the center), whereas the fatty acid chains are buried deep in the hydrophobic groove (and therefore unseen) (27) . Ca 2ϩ ion-dependent process (19) . The Ca 2ϩ ions within the Gla domain are in positions very similar to those seen in prothrombin fragment 1 (Protein Data Bank code 2PF2) and factor VIIa (Protein Data Bank code 1DAN).
To determine whether the presence of lipid in the groove is important for protein C binding, the lipid from rsEPCR was extracted and reconstituted with the endogenous lipid extract. Each form was tested for its ability to bind APC measured indirectly by the ability of the rsEPCR to inhibit fluorescently labeled APC binding to endothelial cells that express fulllength EPCR (11) . Our initial studies indicated that the lipid molecule in rsEPCR was very tightly bound since extensive washing in buffer with or without Triton X-100 failed to remove the bound lipid. Compared with native rsEPCR, lipid extraction reduced the ability of EPCR to block activated protein C binding to HUVECs (Fig. 5) . The remaining inhibitory activity could be due either to residual bound lipid or partial retention of activated protein C binding activity. Reconstitution of the lipid derived from rsEPCR restored the inhibitory activity. The lipids alone treated by the reconstitution approach had no inhibitory activity (data not shown). The results suggest that the bound lipid is important for rsEPCR-protein C interaction, possibly related to maintaining EPCR structure.
Some potentially important biological proposals can be derived from the structure. A model of intact APC can be built by annealing the Gla domain shown in this structure with the remainder of the APC structure (20) essentially as described previously (10) . The C-terminal tail of EPCR would be inserted into the membrane, while activated protein C would bind at nearly the opposite end of EPCR and point away from the membrane surface. This would be predicted to elevate the active site about 35 Ϯ 5 Å further from the membrane than would occur if activated protein C were bound directly to phospholipid. The altered distance of the active site from the membrane surface could favor cleavage of cell surface proteins and might contribute to the observed EPCR dependence of some cell signaling events (21) .
The structure of EPCR helps to explain why it can function without ␤ 2 -microglobulin and the ␣3 domain. In CD1 proteins, the ␣3 domain is positioned on the opposite side of the ␤-sheet from the ligand binding groove and diagonally opposite to the protein C binding site. The residues in the ␤-sheet that interact with the ␣3 domain in CD1d are not conserved in EPCR. Hydrophobic interactions exist between the CD1d ␤-sheet and ␤ 2 -microglobulin, which is located between ␣1␣2 and ␣3 domains. Although EPCR has hydrophobic residues at that region, carbohydrates in that region of EPCR would prevent interaction with ␤ 2 -microglobulin.
Despite its relatively small size, EPCR can bind three ligands simultaneously: proteinase 3, protein C/APC, and phospholipid. The lipid is required for protein C binding, but further characterization of the lipid binding specificity of EPCR and analysis of the role of the lipid in cellular trafficking and EPCR-proteinase 3 interactions remain to be completed.
The structure of rsEPCR with its tightly bound phospholipid may provide insights into how CD1 family members bind lipids. Most of the residues contacting the lipid in EPCR are identical or highly conserved in CD1d, suggesting that CD1d binds lipids for antigen presentation in a manner analogous to EPCR. It is tempting to speculate that EPCR may share with CD1d (22) the ability to present lipid antigens, to play a role in host defense from infection, and perhaps, when compromised, to augment autoimmunity. The latter possibility would be consistent with the observation that anti-phospholipid antibodies associated with thrombosis often have a more dramatic impact on the protein C anticoagulant pathway than on procoagulant complexes (23) . Given that EPCR-null mice exhibit early embryonic lethality (24) , proof of these hypotheses will require improved strategies to acquire viable mice for this analysis.
